Medindia

X

Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock

Tuesday, December 16, 2008 General News J E 4
Advertisement
WALTHAM, Mass., Dec. 15 On December 10, 2008, Inverness Medical Innovations, Inc. (Amex: IMA), a leading provider of near-patient diagnostics, monitoring and health management solutions, declared a dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (Amex: IMA.PR.B). The dividend will be paid in shares of Series B stock in an amount per share equal to the quotient of (a) $3.00 divided by (b) 97% of the average of the volume-weighted average price per share of the Series B stock on the American Stock Exchange for each of the five consecutive trading days ending on the second trading day immediately prior to the record date of the dividend. Inverness will pay cash in lieu of any fractional shares resulting from the dividend. The dividend is payable on January 15, 2009 to holders of record of Series B stock at the close of business on January 2, 2009.

Such payment will cover the amount of dividends accrued from October 1, 2008 through December 31, 2008.

For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.



By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.



SOURCE Inverness Medical Innovations, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Pets Best Announces New Underwriter for Pet Insura...
S
VETORYL(R) (Trilostane) Receives FDA Approval